Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial


Mechelen, Belgium; 29 September 2020, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of a first patient in their psoriasis trial, one of three patient trials currently recruiting to evaluate efficacy and safety of Toledo compound GLPG3970. Furthermore, Galapagos plans to unveil the novel Toledo target class and share GLPG3970 Phase 1 data at its inaugural Toledo Roundtable to be held virtually on 27 October 2020.

Original post:
Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial

Related Posts